5 completed, 1 withdrawn. 6 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 5, Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow Arthroplasty, Replacement, Hip: new trials by email Literature Review of Arthroplasty, Replacement, Hip trials Research Report on Arthroplasty, Replacement, Hip
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dimolegin® (60 mg) Given Once Daily in Patients Undergoing Total Hip or Knee Replacement Compared to Enoxaparin Sodium enoxaparin, Dimolegin, Dimolegin placebo - Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee | Phase 3 | Completed | Avexima Diol LLC | 215 | 2024-07-22 | 2026-01-16 |
| Does Testosterone Therapy Improve Patient-Reported Outcomes in Age-Related Testosterone Deficient Patients Undergoing Total Hip Replacement: A Randomized-Controlled Trial Testosterone Therapy, No Testosterone Therapy - Arthroplasty, Replacement, Hip | Phase 3 | Withdrawn | American Hip Institute | 2019-11-01 | 2023-02-10 | |
| Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038) Sugammadex, neostigmine and glycopyrrolate or atropine, Placebo to neostigmine - Neuromuscular Blockade, Arthroplasty, Replacement, Hip | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1198 | 2011-10-12 | 2021-02-12 |
| A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery YM150, enoxaparin - Venous Thromboembolism, Arthroplasty, Replacement, Hip | Phase 2 / Phase 3 | Completed | Astellas Pharma Europe B.V. | 1992 | 2009-04-01 | 2015-10-27 |
| Total Hip Replacement Study With XRP4563 (Enoxaparin Sodium) Enoxaparin sodium - Arthroplasty, Replacement, Hip | Phase 3 | Completed | Sanofi | 156 | 2006-06-01 | 2009-03-27 |
| Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery dabigatran etexilate, enoxaparin - Thromboembolism, Arthroplasty, Replacement, Hip | Phase 3 | Completed | Boehringer Ingelheim | 3494 | 2004-11-01 | 2014-05-19 |
Thrombosis (2) · Venous Thromboembolism (2) · Thromboembolism (1)
Cardiovascular Diseases (4) · Embolism and Thrombosis (4) · Vascular Diseases (4) · Thromboembolism (2)
Enoxaparin (3) · enoxaparin sodium (2) · (+-)-(1'R*,2'S*,6'R*)-(2-hydroxy-4,6-dimethoxyphenyl)(3'-methyl-2'-(3''-methylbut-2''-enyl)-6-phenylcyclohex-3'-enyl)methanone (1) · Atropine (1) · Dabigatran (1) · Glycopyrrolate (1) · Neostigmine (1) · Sugammadex (1)
American Hip Institute (1) · Astellas Pharma Europe B.V. (1) · Avexima Diol LLC (1) · Boehringer Ingelheim (1) · Merck Sharp & Dohme LLC (1) · Sanofi (1)
Australia (2) · Austria (2) · Czechia (2) · Denmark (2) · Finland (2) · Germany (2) · Hungary (2) · Italy (2) · Norway (2) · Poland (2) · Russia (2) · South Africa (2) · Spain (2) · Sweden (2) · United States (2)
PMID 17869635, PMID 22709460, PMID 22995531, PMID 24136153, PMID 25208233, PMID 26578849
2004 (1), 2008 (1)